Published research to date related to Sigma proteins and Cancer has been conducted with compounds not developed by Advantx Pharmaceuticals Inc. Our therapeutic candidates targeting Sigma receptors are the first pharmaceutical-grade compounds in development with clean molecules and unambiguous activity, far superior in potency, selectivity, safety, and efficacy to all others tested to date.
